ストックスクリーナーアプリを入手
24.76
1.71%
-0.39
Pfizer Inc (PFE) 最新ニュース
Pfizer shares may move 3% around Aug. 4 earnings release - Investing.com
Pfizer (PFE) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - Yahoo Finance
Is Wall Street Bullish or Bearish on Pfizer Stock? - Barchart.com
Pfizer (NYSE:PFE) Shares Gain Pre-Earnings as 7% Dividend Undergoes Cash-Flow Scrutiny - TechStock²
Pfizer price shows cautious gainsForecast today28-07-2026 - Economies.com
Quantinuum, NVIDIA Corporation, and Pfizer Inc Transformer Models Now Generate Quantum Circuits for Molecular Models - Quantum Zeitgeist
Pfizer Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 - marketscreener.com
PFIZER: Q1 FY27 saw higher revenue and profit, with EPS up and strong equity despite exceptional costs - TradingView
Pfizer Inc Lobbyists, 2026 - OpenSecrets
City stops construction at downtown office-to-resi conversion after Pfizer project scare - Crain's New York Business
Can Pfizer (NYSE:PFE) Turn Its Cancer & Obesity Reset Into A New Chapter? - Kalkine Media
Pfizer and Eisai Commence Co-promotion of "NURTEC(R)" for the Acute Treatment and Prophylaxis (Preventive Treatment) of Migraine - marketscreener.com
Pfizer: Calling The BottomThe Patent Cliff Is Real, But The Valuation Has Fallen Too Far - Seeking Alpha
Former Pfizer HQ Evacuation Puts Office Conversions Under Structural Scrutiny - StreetInsider
Pfizer (NYSE:PFE) edges up as low-multiple pharma draws value notice this week - Kalkine Media
GOP Congressman Slams JD Vance's Silence Over CDC's $1.24 Billion Pfizer COVID Vaccine Contracts: 'Why Is - Benzinga
Did FDA’s Priority Review of TALZENNA plus XTANDI in Earlier Prostate Cancer Just Shift Pfizer's (PFE) Investment Narrative? - Yahoo Finance
Pfizer: Board meeting tomorrow; Shares decline 0.62 percent - TradingView
Is Pfizer (PFE) Undervalued On Its FDA Priority Review In Prostate Cancer? - simplywall.st
Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026 - GlobeNewswire Inc.
PFE Stock Quote Price and Forecast - CNN
Pfizer's Dividend Yield Looks Almost Too Good. Here's Why Management Isn't Worried. - Yahoo Finance
Pfizer stock stabilizes as oncology and vaccine pipeline shapes outlook - AD HOC NEWS
Full Fed. Circ. Urged To Reconsider Pfizer's Paxlovid IP Win - Law360
Pfizer’s ex-comms leader joins Vantage Data Centers - Medical Marketing and Media
Pfizer stock trades steadily as recent earnings and pipeline shape investor sentiment - AD HOC NEWS
How Investors May Respond To Pfizer (PFE) Prostate Cancer Combo Drug Label Expansion Push - simplywall.st
Samsung, Celltrion Join Nectin-4 ADC Race, Challenging Pfizer's Padcev Dominance - finance.biggo.com
Is Pfizer's 7% Dividend Yield Too Good to Be True? Here's the Straight Answer - The Globe and Mail
Enanta Was First to File. Pfizer Still Won. The Difference Was One Digit. - JD Supra
Pfizer building incident pits banner project with a conversion pitfall - The Real Deal
Pfizer (NYSE:PFE) Leads Healthcare Focus on Balance-Sheet Strength - Kalkine Media
Curated Wealth Partners LLC's Pfizer Inc(PFE) Holding History - GuruFocus
Pfizer stock trades steady as Pfizer India posts stronger FY 2024 earnings - Ad-hoc-news.de
Arkansas Sues Pfizer, J&J, Others Over Drug Discount Access - Bloomberg Law News
Pfizer stock steadies as investors weigh pipeline progress and recent earnings - Ad-hoc-news.de
Pfizer Prevnar 20 by Pfizer Inc.broader adult protection in one syringe - Ad-hoc-news.de
Pfizer Inc (0Q1N) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
What Makes Pfizer (NYSE:PFE) Stand Out in the S&P 500? - Kalkine Media
Pfizer (PFE) Secures Priority Review for Talzenna in Prostate Ca - GuruFocus
Pfizer’s prostate cancer drug combination gets US FDA priority review - 1470 & 100.3 WMBD
Pfizer's prostate cancer drug combination gets US FDA priority review - Reuters
FDA accepts Pfizer filing for Talzenna-Xtandi prostate cancer use - Investing.com
Pfizer trial: TALZENNA combo cut progression-or-death risk 52% - Stock Titan
Bluesight Partners with Pfizer to Integrate SmartDose™ Source-Tagged Medications into KitCheck - HIT Consultant
Pfizer (PFE) Faces New Patent Lawsuits Over Covid 19 Vaccine Technology - simplywall.st
Biogen, Pfizer vet joins Formation Bio as CSO - The Pharma Letter
Pfizer (NYSE:PFE) Oncology Growth Faces A Major Valuation Test - Kalkine Media
Pfizer stock steadies as investors weigh post-COVID revenue mix and pipeline milestones - Ad-hoc-news.de
Sanofi reprimanded for disparaging Pfizer’s RSV vaccine - Fierce Pharma
Prevnar 20 by Pfizerbroader pneumococcal protection for adults - Ad-hoc-news.de
Pfizer (PFE) Stock Seems Fairly Priced As Oncology Approvals Build - simplywall.st
PR News | Pfizer Pro Harnaga Takes Vantage Data PostTue., Jul. 21, 2026 - O'Dwyer's PR
What to Watch in Pfizer's Non-Oncology Portfolio This Earnings Season - Yahoo Finance
8 Lessons I’ve Learned as a Cancer Survivor - Pfizer
Tingting Zhang-Kharas Appointed Vice President, Search & Evaluation, Oncology at Pfizer - hrtoday.in
Pfizer building’s collapse scare tests whether New Yorkers will forget and rent anyway - Crain's New York
From Vaccines to Air Traffic: Poland’s Billion-Euro Dispute with Pfizer - finchannel
Pfizer stock trades steady as recent earnings and pipeline updates frame valuation - Ad-hoc-news.de
Pfizer (PFE) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
Pfizer Suspends Popular Menopause Cream in India - Benzinga
Axios C-Suite: Pfizer CEO on biotech's China warning - Axios
Pfizer (PFE) Faces New International Patent Lawsuits Over Covid 19 Vaccine - Yahoo Finance
Pfizer stock steadies as investors weigh recent earnings and pipeline progress - Ad-hoc-news.de
Is Trending Stock Pfizer Inc. (PFE) a Buy Now? - Yahoo Finance
Unions seize on Pfizer conversion scare to push for contracts, reforms - The Real Deal
1.09%
0.00%
大文字化:
|
ボリューム (24 時間):